期刊文献+

以聚乙二醇-聚己内酯为载体的靶向药物递送系统研究进展 被引量:1

Advances of Targeted Drug Delivery Based on PEG-PCL
下载PDF
导出
摘要 近年来,生物可降解材料具有优异的生物可降解性能、良好的生物相容性和力学性能,在医药领域具有广阔的应用前景。两亲性聚乙二醇-聚己内酯(poly(ethylene glycol)-poly(ε-caprolactone),PEG-PCL)二嵌段共聚物作为药物递送载体的研究也逐步深入。在PEG-PCL系统表面修饰多种配体,如多肽、抗体、碳水化合物、核酸适体以及小分子等,可以显著增强药物的生物利用度和治疗效果,实现靶向给药。该文对以PEG-PCL为载体,不同配体介导的靶向递药研究进行综述,以期为PEG-PCL载体在靶向递药系统中的应用提供思路和方法。 In recent years ,biodegradable materials have been widely used in pharmaceutical field because of the excellent biodegradability,biocompatibility and mechanical property. Among them, poly (ethylene glycol)-poly (e-caprolactone) copolymers (PEG-PCL) has been widely used in drug delivery system. The drug delivery system based on PEG-PCL can be modified with various ligands, such as peptides, antibodies, carbohydrates, aptamers and small molecules for enhancing the bioavailability and therapeutic effect, achieving targeted drug delivery. In this paper,the research progress of targeted drug delivery based on PEG-PCL is reviewed, in order to provide ideas and methods for the applications of PEG-PCL in targeted drug delivery system.
作者 苏晓梅 张丹参 SU Xiao-mei;ZHANG Dan-shen(Hebei University of Science and Technology, Shijiazhuang, 050000, Chin)
机构地区 河北科技大学
出处 《神经药理学报》 2016年第5期22-28,共7页 Acta Neuropharmacologica
基金 国家自然科学基金项目(No.81274005) 河北省自然科学基金项目(No.H2016208058) 河北省教育厅科学技术研究重点项目(No.ZD 2016009)
关键词 聚乙二醇-聚己内酯 靶向 药物递送系统 poly(ethylene glycol)-poly(e-caprolactone) copolymers (PEG-PCL) targeted drug delivery system
  • 相关文献

参考文献1

二级参考文献16

  • 1严世荣,王立林,邱方城.细胞穿膜肽的研究进展[J].生物技术通讯,2006,17(5):796-798. 被引量:6
  • 2MAEDA N, TAKEUCHI Y, TAKADA M, et al. Anti-neovascular therapy by use of tumor neovasculature- targeted long-circulating liposome [J]. J Control Release, 2004, 100(1): 41-52.
  • 3KATANASAKAA Y, IDAA T, ASAIA T, et al. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes [J]. Inter J Pharm, 2008, 360(1/2): 219-224.
  • 4ASAI T, MIYAZAWA S, MAEDA N, et al. Antineovascular therapy with angiogenic vesseltargeted polyethyleneglycol- shielded liposomal DPP-CNDAC [J]. Cancer Sci, 2008, 99(5): 1029-1033.
  • 5TORCHILIN V P, LEVCHENKO T S. TAT-liposomes: a novel intracellular drug carrier [J]. Cur Protein Pept Sei, 2003, 4(2): 133-140.
  • 6DAGAR S, KRISHNADAS A, RUBINSTEIN I, et al. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies [J]. J Control Release, 2003, 91(1/2): 123-133.
  • 7TORCHILIN V P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging [J]. AAPS J, 2007, 9(2): 128-147.
  • 8PASTOR/NO F, BRIGNOLE C, MARIMPIETRI D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy [J]. Cancer Res, 2003, 63(21): 7400-7409.
  • 9LO A, LIN C T, WU H C. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery [J]. Mol Cancer Ther, 2008, 7(3): 579-589.
  • 10XIONG X B, HUANG Y, LU W L, et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo [J]. J Pharm Sci, 2005, 94(8): 1782-1793.

共引文献8

同被引文献16

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部